Helius Medical Technologies Inc. (NASDAQ: HSDT) stock jumped 145.34% on Friday to $1.58 against a previous-day closing price of $0.64. With 39.76 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.12 million shares. During the session, the Medical Devices company that operates in wider Healthcare sector, reached to the highest price of $2.7600 whereas the lowest price it dropped to was $1.2800. The 52-week range on HSDT shows that it touched its highest point at $16.22 and its lowest point at $0.64 during that stretch. It currently has a 1-year price target of $25.00. Beta for the stock currently stands at 0.76.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of HSDT was up-trending over the past week, with a rise of 60.00%, but this was up by 19.70% over a month. Three-month performance dropped to -41.04% while six-month performance fell -61.08%. The stock lost -89.69% in the past year, while it has lost -69.56% so far this year. A look at the trailing 12-month EPS for HSDT yields -7.05 with Next year EPS estimates of -2.25. For the next quarter, that number is -1.12. This implies an EPS growth rate of 70.50% for this year and 24.80% for next year.
Float and Shares Shorts:
At present, 3.13 million HSDT shares are outstanding with a float of 3.06 million shares on hand for trading. On Jul 14, 2022, short shares totaled 59250.0, which was 1.56% higher than short shares on Jun 14, 2022. In addition to Mr. Dane Carl Andreeff as the firm’s Pres, CEO & Director, Mr. Jeffrey S. Mathiesen CPA, CPA serves as its CFO, Treasurer, Sec. & Director.
Through their ownership of 28.22% of HSDT’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 6.43% of HSDT, in contrast to 22.94% held by mutual funds. Shares owned by individuals account for 0.57%. As the largest shareholder in HSDT with 7.32% of the stake, Columbus Capital Management LLC holds 278,010 shares worth 278,010. A second-largest stockholder of HSDT, AIGH Capital Management LLC, holds 255,400 shares, controlling over 6.73% of the firm’s shares. Kepos Capital LP is the third largest shareholder in HSDT, holding 75,000 shares or 1.98% stake. With a 0.27% stake in HSDT, the Fidelity Extended Market Index Fu is the largest stakeholder. A total of 10,339 shares are owned by the mutual fund manager. The Fidelity Series Total Market Inde, which owns about 0.10% of HSDT stock, is the second-largest Mutual Fund holder. It holds 3,762 shares valued at 4439.0. Fidelity Nasdaq Composite Index F holds 0.07% of the stake in HSDT, owning 2,717 shares worth 3206.0.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for HSDT since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With HSDT analysts setting a high price target of $25.00 and a low target of $25.00, the average target price over the next 12 months is $25.00. Based on these targets, HSDT could surge 1482.28% to reach the target high and rise by 1482.28% to reach the target low. Reaching the average price target will result in a growth of 1482.28% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. HSDT will report FY 2022 earnings on 03/16/2023. Analysts have provided yearly estimates in a range of -$4.18 being high and -$4.18 being low. For HSDT, this leads to a yearly average estimate of -$4.18. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Helius Medical Technologies Inc. surprised analysts by -$0.02 when it reported -$1.15 EPS against a consensus estimate of -$1.13. The surprise factor in the prior quarter was -$0.15. Based on analyst estimates, the high estimate for the next quarter is -$1.12 and the low estimate is -$1.12. The average estimate for the next quarter is thus -$1.12.
Summary of Insider Activity:
Insiders traded HSDT stock several times over the past three months with 4 Buys and 0 Sells. In these transactions, 24,196 shares were bought while 0 shares were sold. The number of buy transactions has increased to 29 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 108,978 while 0 shares were sold.